The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting

G. Dranitsaris, A. Molassiotis, M. Clemons, E. Roeland, Lee Schwartzberg, P. Dielenseger, K. Jordan, A. Young, M. Aapro

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of≥ grade 2 CINV (≥2 vomiting episodes or a decrease in oral intake due to nausea) from days 0 to 5 post-chemotherapy was developed. Patients and methods: Data from 1198 patients enrolled in one of the five non-interventional CINV prospective studies were pooled. Generalized estimating equations were used in a backwards elimination process with the P-value set at<0.05 to identify the relevant predictive factors. A risk scoring algorithm (range 0-32) was then derived from the final model coefficients. Finally, a receiver-operating characteristic curve (ROCC) analysis was done to measure the predictive accuracy of the scoring algorithm. Results: Over 4197 chemotherapy cycles, 42.2% of patients experienced≥grade 2 CINV. Eight risk factors were identified: patient age<60 years, the first two cycles of chemotherapy, anticipatory nausea and vomiting, history of morning sickness, hours of sleep the night before chemotherapy, CINV in the prior cycle, patient self-medication with non-prescribed treatments, and the use of platinum or anthracycline-based regimens. The ROC analysis indicated good predictive accuracy with an areaunder- the-curve of 0.69 (95% CI: 0.67-0.70). Before to each cycle of therapy, patients with risk scores≥16 units would be considered at high risk for developing≥grade 2 CINV. Conclusions: The clinical application of this prediction tool will be an important source of individual patient risk information for the oncology clinician and may enhance patient care by optimizing the use of the antiemetics in a proactive manner.

Original languageEnglish (US)
Article numbermdx100
Pages (from-to)1260-1267
Number of pages8
JournalAnnals of Oncology
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Nausea
Vomiting
Drug Therapy
Neoplasms
Antiemetics
ROC Curve
Anticipatory Vomiting
Morning Sickness
Self Medication
Anthracyclines
Platinum
Patient Care
Sleep
Prospective Studies
Guidelines

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Dranitsaris, G., Molassiotis, A., Clemons, M., Roeland, E., Schwartzberg, L., Dielenseger, P., ... Aapro, M. (2017). The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting. Annals of Oncology, 28(6), 1260-1267. [mdx100]. https://doi.org/10.1093/annonc/mdx100

The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting. / Dranitsaris, G.; Molassiotis, A.; Clemons, M.; Roeland, E.; Schwartzberg, Lee; Dielenseger, P.; Jordan, K.; Young, A.; Aapro, M.

In: Annals of Oncology, Vol. 28, No. 6, mdx100, 01.06.2017, p. 1260-1267.

Research output: Contribution to journalArticle

Dranitsaris, G, Molassiotis, A, Clemons, M, Roeland, E, Schwartzberg, L, Dielenseger, P, Jordan, K, Young, A & Aapro, M 2017, 'The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting', Annals of Oncology, vol. 28, no. 6, mdx100, pp. 1260-1267. https://doi.org/10.1093/annonc/mdx100
Dranitsaris, G. ; Molassiotis, A. ; Clemons, M. ; Roeland, E. ; Schwartzberg, Lee ; Dielenseger, P. ; Jordan, K. ; Young, A. ; Aapro, M. / The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting. In: Annals of Oncology. 2017 ; Vol. 28, No. 6. pp. 1260-1267.
@article{7c76ee3b05ff427f97e208859151c48d,
title = "The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting",
abstract = "Background: Despite the availability of effective antiemetics and evidence-based guidelines, up to 40{\%} of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of≥ grade 2 CINV (≥2 vomiting episodes or a decrease in oral intake due to nausea) from days 0 to 5 post-chemotherapy was developed. Patients and methods: Data from 1198 patients enrolled in one of the five non-interventional CINV prospective studies were pooled. Generalized estimating equations were used in a backwards elimination process with the P-value set at<0.05 to identify the relevant predictive factors. A risk scoring algorithm (range 0-32) was then derived from the final model coefficients. Finally, a receiver-operating characteristic curve (ROCC) analysis was done to measure the predictive accuracy of the scoring algorithm. Results: Over 4197 chemotherapy cycles, 42.2{\%} of patients experienced≥grade 2 CINV. Eight risk factors were identified: patient age<60 years, the first two cycles of chemotherapy, anticipatory nausea and vomiting, history of morning sickness, hours of sleep the night before chemotherapy, CINV in the prior cycle, patient self-medication with non-prescribed treatments, and the use of platinum or anthracycline-based regimens. The ROC analysis indicated good predictive accuracy with an areaunder- the-curve of 0.69 (95{\%} CI: 0.67-0.70). Before to each cycle of therapy, patients with risk scores≥16 units would be considered at high risk for developing≥grade 2 CINV. Conclusions: The clinical application of this prediction tool will be an important source of individual patient risk information for the oncology clinician and may enhance patient care by optimizing the use of the antiemetics in a proactive manner.",
author = "G. Dranitsaris and A. Molassiotis and M. Clemons and E. Roeland and Lee Schwartzberg and P. Dielenseger and K. Jordan and A. Young and M. Aapro",
year = "2017",
month = "6",
day = "1",
doi = "10.1093/annonc/mdx100",
language = "English (US)",
volume = "28",
pages = "1260--1267",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting

AU - Dranitsaris, G.

AU - Molassiotis, A.

AU - Clemons, M.

AU - Roeland, E.

AU - Schwartzberg, Lee

AU - Dielenseger, P.

AU - Jordan, K.

AU - Young, A.

AU - Aapro, M.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of≥ grade 2 CINV (≥2 vomiting episodes or a decrease in oral intake due to nausea) from days 0 to 5 post-chemotherapy was developed. Patients and methods: Data from 1198 patients enrolled in one of the five non-interventional CINV prospective studies were pooled. Generalized estimating equations were used in a backwards elimination process with the P-value set at<0.05 to identify the relevant predictive factors. A risk scoring algorithm (range 0-32) was then derived from the final model coefficients. Finally, a receiver-operating characteristic curve (ROCC) analysis was done to measure the predictive accuracy of the scoring algorithm. Results: Over 4197 chemotherapy cycles, 42.2% of patients experienced≥grade 2 CINV. Eight risk factors were identified: patient age<60 years, the first two cycles of chemotherapy, anticipatory nausea and vomiting, history of morning sickness, hours of sleep the night before chemotherapy, CINV in the prior cycle, patient self-medication with non-prescribed treatments, and the use of platinum or anthracycline-based regimens. The ROC analysis indicated good predictive accuracy with an areaunder- the-curve of 0.69 (95% CI: 0.67-0.70). Before to each cycle of therapy, patients with risk scores≥16 units would be considered at high risk for developing≥grade 2 CINV. Conclusions: The clinical application of this prediction tool will be an important source of individual patient risk information for the oncology clinician and may enhance patient care by optimizing the use of the antiemetics in a proactive manner.

AB - Background: Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of≥ grade 2 CINV (≥2 vomiting episodes or a decrease in oral intake due to nausea) from days 0 to 5 post-chemotherapy was developed. Patients and methods: Data from 1198 patients enrolled in one of the five non-interventional CINV prospective studies were pooled. Generalized estimating equations were used in a backwards elimination process with the P-value set at<0.05 to identify the relevant predictive factors. A risk scoring algorithm (range 0-32) was then derived from the final model coefficients. Finally, a receiver-operating characteristic curve (ROCC) analysis was done to measure the predictive accuracy of the scoring algorithm. Results: Over 4197 chemotherapy cycles, 42.2% of patients experienced≥grade 2 CINV. Eight risk factors were identified: patient age<60 years, the first two cycles of chemotherapy, anticipatory nausea and vomiting, history of morning sickness, hours of sleep the night before chemotherapy, CINV in the prior cycle, patient self-medication with non-prescribed treatments, and the use of platinum or anthracycline-based regimens. The ROC analysis indicated good predictive accuracy with an areaunder- the-curve of 0.69 (95% CI: 0.67-0.70). Before to each cycle of therapy, patients with risk scores≥16 units would be considered at high risk for developing≥grade 2 CINV. Conclusions: The clinical application of this prediction tool will be an important source of individual patient risk information for the oncology clinician and may enhance patient care by optimizing the use of the antiemetics in a proactive manner.

UR - http://www.scopus.com/inward/record.url?scp=85021078200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021078200&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx100

DO - 10.1093/annonc/mdx100

M3 - Article

VL - 28

SP - 1260

EP - 1267

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

M1 - mdx100

ER -